Endocannabinoids and basal ganglia functionality

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 257-267

  Fernandez Ruiz J ^a   Lastres Becker, I ^a   Cabranes, A ^a   Gonzalez S ^a   Ramos, J A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; LEVODOPA; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; RIMONABANT; CANNABINOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; ICOSANOID;

ALZHEIMER DISEASE; BASAL GANGLION; DRUG RECEPTOR BINDING; HUMAN; HUNTINGTON CHOREA; HYPOKINESIA; MOTOR DYSFUNCTION; MOVEMENT (PHYSIOLOGY); MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; EXTRAPYRAMIDAL SYNDROME; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BASAL GANGLIA; BASAL GANGLIA DISEASES; CANNABINOIDS; EICOSANOIDS; ENDOCANNABINOIDS; HUMANS; MOTOR ACTIVITY; MOVEMENT DISORDERS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SYNAPTIC TRANSMISSION;

EID: 0036019411     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0350     Document Type: Article

References (104)

1. Brain cannabinoid systems as targets for the therapy of neurological disorders
2. Motor actions of cannabinoids in the basal ganglia output nuclei
3. The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological and therapeutic aspects
4. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents
5. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
6. 9-tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats
7. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
8. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: Role of nigrostriatal dopaminergic neurons
9. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function
10. Activational role of cannabinoids on movement
11. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice
12. 9-tetrahydrocannabinol: Possible involvement of nigrostriatal dopaminergic alterations
13. 9-tetrahydrocannabinol to produce marked catalepsy in mice
14. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia
15. 9-tetrahydrocannabinol treatment
16. 9-tetrahyrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats
17. 9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats
18. 9-tetrahydrocannabinol
19. Cannabinol and cannabidiol in combination: Temperature, open-field activity, and vocalization
20. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand
21. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide
22. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues
23. 9-tetrahydrocannabinol-induced responses and apparent agonist activity
24. 1 cannabinoid receptor antagonist SR141716A affects A9 dopamine neuronal activity in the rats
25. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA
26. Involvement of GABA-B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors
27. The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake
28. 9-THC reduces GABA uptake in the globus pallidus
29. 1 receptors and alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
30. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist
31. Local effects of cannabinoids on spontaneus activity and evoked inhibition in the globus pallidus
32. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus
33. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum
34. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat
35. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata
36. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum
37. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
38. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat
39. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry
40. 1 receptors in the rat central nervous system
41. Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study
42. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum
43. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus
44. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function
45. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period
46. The neostriatal mosaic: Multiple levels of compartmental organization
47. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
48. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
49. Enhanced levels of endocannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
50. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial purification
51. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry
52. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
53. Age-related loss of cannabinoid of cannabinoid receptor binding sites and mRNA in the rat striatum
54. 35S]-GTPγS binding in the basal ganglia of aged rats
55. Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats
56. The role of cannabinoids in neurodegenerative diseases
57. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease
58. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington's disease
59. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus
60. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains
61. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's disease and MPTP-treated marmosets
62. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats
63. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudateputamen
64. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease
65. 1 receptors in the basal ganglia of a transgenic model of Huntington's disease
66. Cannabinoid receptor messenger RNA levels decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
67. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain
68. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease
69. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis
70. Cannabinoids control spasticity and tremor in a multiple sclerosis model
71. Endocannabinoids control spasticity in experimental multiple sclerosis
72. Effective treatment of Tourette's syndrome with marijuana
73. Cannabinoids: Posible role in the pathophysiology of Gilles de la Tourette-syndrome
74. 9-tetrahydrocannabinol
75. Cannabis in movement disorders
76. Recent advances in understanding the pathogenesis of Huntington's disease
77. 3-Nitropropionic acid's lethal triplet: Cooperative pathways of neurodegeneration
78. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia
79. Nabilone increases choreatic movements in Huntington's disease
80. Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor
81. The anandamide transport inhibitor AM404 activates vanilloid receptors
82. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human
83. Functional changes in the basal ganglia circuitry in Parkinson's disease
84. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study
85. Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
86. The neuroal mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease
87. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates
88. The subthalamic nucleus and tremor in Parkinson's disease
89. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease
90. The cannabinoid agonists WIN55,212-2 and CP55,940 attenuate rotational behaviour induced by a dopamine D1 but not D2 agonist in rats with unilateral lesions of the nigrostriatal pathway
91. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease
92. Multiple sclerosis: More than inflammation and demyelination
93. 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis
94. Suppression of experimental autoimmune encephalomyelitis by cannabinoids
95. Cannabinoids and multiple sclerosis
96. The perceived effects of smoked cannabis on patient with multiple sclerosis
97. Tetrahydrocannabinol for tremor in multiple sclerosis
98. 9-THC in the treatment of spasticity associated with multiple sclerosis
99. Nabilone in the treatment of multiple sclerosis
100. Short-term effects of smoking marihuana on balance in patients with multiple sclerosis and normal volunteers
101. Extrapyramidal features in Alzheimer's disease
102. Current cannabis use and tardive diskinesia
103. (+)-WIN55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters
104. Differential association between chronic cannabis use and brain function deficits